Unveiling Patient Experiences in Testicular Cancer Clinical Trials

Sponsor
Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05928377
Collaborator
(none)
500
1
24
20.8

Study Details

Study Description

Brief Summary

Clinical research participation has historically been heavily biased toward specific demographics.

Several people will be invited to enroll in this study so that it may collect a variety of data about testicular cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.

People with testicular cancer who are invited to take part in medical research will benefit from the analysis of the data.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Crossover
    Time Perspective:
    Prospective
    Official Title:
    Patient Perspectives in Testicular Cancer Clinical Trials: Insights Into Participating in Studies for Testicular Cancer
    Anticipated Study Start Date :
    Jul 1, 2024
    Anticipated Primary Completion Date :
    Jul 1, 2025
    Anticipated Study Completion Date :
    Jul 1, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Number of testicular cancer patients who decide to enroll in a clinical trial [3 months]

    2. Rate of testicular cancer patients who remain in a clinical trial to trial completion [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

    • Diagnosis of testicular cancer

    • No prior treatment for testicular cancer

    Exclusion Criteria:
    • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

    • Enrolled in another research study

    • Inability to provide written informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Power Life Sciences San Francisco California United States 94107

    Sponsors and Collaborators

    • Power Life Sciences Inc.

    Investigators

    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Power Life Sciences Inc.
    ClinicalTrials.gov Identifier:
    NCT05928377
    Other Study ID Numbers:
    • 80505443
    First Posted:
    Jul 3, 2023
    Last Update Posted:
    Jul 3, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Power Life Sciences Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 3, 2023